Jasper Therapeutics Reports $144.5 Million Q3 Net Loss, Advances Kidney Disease Studies
Jasper Therapeutics reported a net loss of $144.5 million for the third quarter of 2026, compared with $18.7 million a year earlier, following its acquisition of Kira Pharmaceuticals. Revenue was $8.0 million, while operating expenses included a $129.5 million charge for acquired in-process researc…